Introduction: Median duration of therapy with the first JAK1/2 inhibitor ruxolitinib (RUX)
approved for patients with intermediate or high-risk myelofibrosis (MF) is about 3 years …

Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral
inhibitor of Janus kinase (JAK) 1 and JAK2. Ruxolitinib has been approved for the treatment …

The JAK1 and JAK2 inhibitor ruxolitinib has approved indications in myelofibrosis, a BCR-
AB1-negative myeloproliferative neoplasm associated with progressive bone marrow …

Over the last decade, unparalleled advances have been made within the field of
'Philadelphia chromosome'-negative myeloproliferative neoplasms (MPN) regarding both …

Myelofibrosis is a myeloproliferative neoplasm characterized by bone marrow fibrosis and
extramedullary hematopoiesis. Evolution of myelofibrosis can lead to life‐threatening …

Objective: Myelofibrosis (MF) is a pathologic entity of myeloproliferative neoplasm (MPN)
characterized by bone marrow fibrosis, extramedullary hematopoiesis, splenomegaly, and …

Myelofibrosis (MF) is characterized by chronic inflammation and hyper-activation of the JAK-
STAT pathway. Infections are one of the main causes of morbidity/mortality. Therapy with …

Myelofibrosis (MF) is a clonal myeloproliferative neoplasm, in which the JAK2-V617F
mutation is frequently observed. The appearance in up to 50% of the cases makes the JAK2 …

The Janus kinase (JAK)–inhibitor ruxolitinib decreases constitutional symptoms and spleen
size of myelofibrosis (MF) patients by mechanisms distinct from its anticlonal activity. Here …

Ruxolitinib is the front-line non-palliative treatment for myelofibrosis (MF). However, a
significant number of patients lose or present suboptimal response, are resistant or have …